Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,268 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $7.09, for a total value of $16,080.12. Following the sale, the chief executive officer directly owned 483,997 shares in the company, valued at $3,431,538.73. The trade was a 0.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kevin Lee also recently made the following trade(s):
- On Thursday, July 3rd, Kevin Lee sold 3,193 shares of Bicycle Therapeutics stock. The stock was sold at an average price of $7.44, for a total value of $23,755.92.
Bicycle Therapeutics Stock Up 1.1%
NASDAQ:BCYC traded up $0.09 during midday trading on Thursday, hitting $8.09. The stock had a trading volume of 256,512 shares, compared to its average volume of 397,086. Bicycle Therapeutics PLC Sponsored ADR has a one year low of $6.10 and a one year high of $28.67. The stock has a 50-day moving average of $8.02 and a 200 day moving average of $9.96. The company has a market capitalization of $560.23 million, a price-to-earnings ratio of -2.58 and a beta of 1.41.
Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative return on equity of 25.54% and a negative net margin of 790.07%. The firm had revenue of $9.98 million for the quarter, compared to the consensus estimate of $8.67 million. On average, sell-side analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 earnings per share for the current fiscal year.
Analysts Set New Price Targets
BCYC has been the topic of several analyst reports. Barclays reduced their price objective on Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. B. Riley cut their target price on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC reaffirmed a "buy" rating and set a $29.00 target price on shares of Bicycle Therapeutics in a research note on Friday, May 2nd. Morgan Stanley set a $17.00 target price on Bicycle Therapeutics and gave the company an "equal weight" rating in a research note on Monday, May 5th. Finally, Royal Bank Of Canada cut their target price on Bicycle Therapeutics from $35.00 to $32.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $25.00.
Get Our Latest Research Report on Bicycle Therapeutics
Institutional Trading of Bicycle Therapeutics
Hedge funds have recently bought and sold shares of the stock. Barclays PLC lifted its holdings in Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock worth $37,000 after buying an additional 2,345 shares during the period. GAMMA Investing LLC lifted its holdings in Bicycle Therapeutics by 879.5% during the first quarter. GAMMA Investing LLC now owns 8,982 shares of the company's stock worth $76,000 after buying an additional 8,065 shares during the period. Exchange Traded Concepts LLC lifted its holdings in Bicycle Therapeutics by 90.3% during the first quarter. Exchange Traded Concepts LLC now owns 12,764 shares of the company's stock worth $108,000 after buying an additional 6,057 shares during the period. Cerity Partners LLC purchased a new stake in Bicycle Therapeutics during the first quarter worth $113,000. Finally, Portland Investment Counsel Inc. purchased a new stake in Bicycle Therapeutics during the first quarter worth $127,000. Hedge funds and other institutional investors own 86.15% of the company's stock.
Bicycle Therapeutics Company Profile
(
Get Free Report)
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.
Further Reading
Before you consider Bicycle Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.
While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
